Clinical Trials Browser

INDUSTRY × zenocutuzumab × Clear all

NSCLC Harboring NRG1 Fusion

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 2 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Clinical Trials

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.